Publications by authors named "I Adamsons"
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Lancet Healthy Longev
April 2023
Article Synopsis
- - VERTIS CV was a large clinical trial that aimed to determine the cardiovascular safety and efficacy of the drug ertugliflozin in adults with type 2 diabetes and existing cardiovascular disease, focusing on major adverse cardiovascular events as its main outcome.
- - The trial involved 8,246 participants aged 40 and older across 567 centers in 34 countries, who were randomly assigned to receive either two doses of ertugliflozin or a placebo alongside standard treatment.
- - The study also analyzed how age affected outcomes, particularly for patients aged 65 and older, assessing cardiorenal outcomes, kidney function, and safety indicators during the trial period between December 2013 and April 2017.
Background: The aim of this study was to compare the efficacy and tolerability of preservative-free (PF) and preservative-containing (PC) formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure (IOP).
Methods: A parallel, randomized, double-masked study was conducted. After a 3-week run-in on timolol, patients with ocular hypertension, as confirmed by an IOP ≥22 mmHg, were randomized 1:1 to receive PF or PC dorzolamide/timolol twice daily for 12 weeks.
Purpose: To evaluate the intercurrent factors for the development of open-angle glaucoma (OAG) in ocular hypertensive patients who were enrolled in the European Glaucoma Prevention Study (EGPS).
Design: Randomized, double masked, controlled clinical trial.
Methods: setting: Multicenter.
Purpose: To measure central corneal thickness (CCT) within the participants of the European Glaucoma Prevention Study (EGPS). This study was designed to test if lowering intraocular pressure (IOP) by means of dorzolamide is able to prevent or delay conversion from ocular hypertension to glaucoma.
Design: Randomized, double-masked, controlled, observational clinical trial.
Objective: To test the validity and generalizability of the Ocular Hypertension Treatment Study (OHTS) prediction model for the development of primary open-angle glaucoma (POAG) in a large independent sample of untreated ocular hypertensive individuals and to develop a quantitative calculator to estimate the 5-year risk that an individual with ocular hypertension will develop POAG.
Design: A prediction model was developed from the observation group of the OHTS and then tested on the placebo group of the European Glaucoma Prevention Study (EGPS) using a z statistic to compare hazard ratios, a c statistic for discrimination, and a calibration chi2 for systematic overestimation/underestimation of predicted risk. The 2 study samples were pooled to increase precision and generalizability of a 5-year predictive model for developing POAG.